This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Pharmacologic Approaches to Cognitive Deficits in Alzheimer’s Disease

Elaine R. Peskind, M.D.

Published: April 1, 1998

Article Abstract

This article reviews placebo-controlled studies addressing drug efficacy for the cognitive deficitsof Alzheimer’s disease. Efforts to compensate for the presynaptic cholinergic deficiency in Alzheimer’s disease by pharmacologically inhibiting acetylcholine degradation have been successful in severalclinical trials. Two cholinesterase inhibitors are available for Alzheimer’s disease, and others mostlikely will soon be available. Cholinesterase inhibitors represent the only therapy currently approvedfor the treatment of Alzheimer’s disease. The antioxidant drugs alpha-tocopherol (vitamin E) andselegiline have been demonstrated marginally superior to placebo for slowing functional deteriorationin patients with moderately advanced Alzheimer’s disease. Epidemiologic studies suggest protectiveeffects against Alzheimer’s disease from postmenopausal estrogen replacement and nonsteroidal antiinflammatorydrugs. Placebo-controlled studies prospectively evaluating the hypotheses generated bythese epidemiologic studies are ongoing.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 59

Quick Links: Cognition , Neurologic and Neurocognitive

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...